Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus GRIFULVIN V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus GRIFULVIN V.
FULVICIN-U/F vs GRIFULVIN V
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Binds to microtubule-associated proteins and disrupts fungal mitotic spindle formation, thereby inhibiting fungal cell division. It also interferes with fungal nucleic acid synthesis.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
500 mg orally once daily (non-microsize formulation) or 250 mg twice daily; typical duration is 4-8 weeks for tinea capitis, 2-6 weeks for tinea corporis, 4-6 weeks for tinea pedis.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Terminal half-life: 9–24 hours. Clinical context: Steady-state achieved in 2–5 days; prolonged in hepatic impairment.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Renal (1% unchanged), fecal (33% as metabolites), biliary (minor). Extensive hepatic metabolism; <1% excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal